Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
treatment of non-small cell lung cancer |
| gptkbp:ATCCode |
L01ED10
|
| gptkbp:brand |
gptkb:Lorbrena
|
| gptkbp:CASNumber |
gptkb:945076-68-4
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:hasInChIKey |
QKQKRCQHZTVNSX-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C21H19FN6O2
|
| gptkbp:hasSMILES |
CC1=NN(C2=C1C=CC(=C2)F)C3=NC(=NC(=C3N)N4CCN(CC4)C)C(=O)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
945076-68-4
|
| gptkbp:isALKInhibitor |
true
|
| gptkbp:isROS1Inhibitor |
true
|
| gptkbp:IUPACName |
(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4',3':4,5]pyrrolo[2,1-b][1,3]benzoxazin-9(13H)-one
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:molecularWeight |
406.42 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Lorlatinib
PF-06463922 |
| gptkbp:bfsParent |
gptkb:Mircera
|
| gptkbp:bfsLayer |
8
|